These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35681653)
41. Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia. Hutspardol S; Sirachainan N; Anurathapan U; Pakakasama S; Songdej D; Chuansumrit A; Sirireung S; Panthangkool W; Hongeng S J Med Assoc Thai; 2013 Jan; 96 Suppl 1():S18-24. PubMed ID: 23724451 [TBL] [Abstract][Full Text] [Related]
42. Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. Montes de Oca C; Castagna L; De Philippis C; Bramanti S; Schiano JM; Pagliardini T; Collignon A; Harbi S; Mariotti J; Granata A; Maisano V; Furst S; Legrand F; Chabannon C; Carlo-Stella C; Santoro A; Blaise D; Devillier R Biol Blood Marrow Transplant; 2020 Dec; 26(12):2299-2305. PubMed ID: 32822845 [TBL] [Abstract][Full Text] [Related]
43. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. Santoro N; Ruggeri A; Labopin M; Bacigalupo A; Ciceri F; Gülbaş Z; Huang H; Afanasyev B; Arcese W; Wu D; Koc Y; Tischer J; Santarone S; Giebel S; Mohty M; Nagler A J Hematol Oncol; 2017 May; 10(1):113. PubMed ID: 28558762 [TBL] [Abstract][Full Text] [Related]
44. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794 [TBL] [Abstract][Full Text] [Related]
45. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Mohty M; Bay JO; Faucher C; Choufi B; Bilger K; Tournilhac O; Vey N; Stoppa AM; Coso D; Chabannon C; Viens P; Maraninchi D; Blaise D Blood; 2003 Jul; 102(2):470-6. PubMed ID: 12649133 [TBL] [Abstract][Full Text] [Related]
46. Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status. Zhang L; Zhang YZ Cancer Biol Med; 2013 Mar; 10(1):1-9. PubMed ID: 23691438 [TBL] [Abstract][Full Text] [Related]
47. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299 [TBL] [Abstract][Full Text] [Related]
48. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569 [TBL] [Abstract][Full Text] [Related]
49. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT. Gutiérrez-García G; Martínez C; Boumendil A; Finel H; Malladi R; Afanasyev B; Tsoulkani A; Wilson KMO; Bloor A; Nikoloudis M; Richardson D; López-Corral L; Castagna L; Cornelissen J; Giltat A; Collin M; Fanin R; Bonifazi F; Robinson S; Montoto S; Peggs KS; Sureda A Br J Haematol; 2022 Feb; 196(4):1018-1030. PubMed ID: 34750806 [TBL] [Abstract][Full Text] [Related]
50. Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. Bazarbachi AH; Reef D; Narvel H; Patel R; Al Hamed R; Vikash S; Neupane K; Atalla E; Thakkar A; Rahman S; Shah U; Adrianzen-Herrera D; Quinn R; Zareef S; Rabinovich E; De Castro A; Joseph F; Gillick K; Mustafa J; Khatun F; Lombardo A; Townsend-Nugent L; Abreu M; Chambers N; Elkind R; Shi Y; Wang Y; Derman O; Gritsman K; Steidl U; Goldfinger M; Kornblum N; Shastri A; Mantzaris I; Bachier-Rodriguez L; Shah N; Cooper D; Verma A; Ye BH; Janakiram M; Sica RA Clin Hematol Int; 2023 Jun; 5(2-3):78-91. PubMed ID: 36918485 [TBL] [Abstract][Full Text] [Related]
51. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057 [TBL] [Abstract][Full Text] [Related]
52. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414 [TBL] [Abstract][Full Text] [Related]
53. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation]. Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286 [No Abstract] [Full Text] [Related]
55. Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. Lwin Y; Kennedy G; Gottlieb D; Kwan J; Ritchie D; Szer J; Milliken S; Browett P; Spencer A; Butler A; Bardy P; Greenwood M; Perera T; He S; McEwan A; Larsen S; Lai H; Purtill D; Tran S; Aarons D; Hamad N Biol Blood Marrow Transplant; 2020 Dec; 26(12):2252-2261. PubMed ID: 32861814 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Li T; Luo C; Zhang J; Wei L; Sun W; Xie Q; Liu Y; Zhao Y; Xu S; Wang L Stem Cell Res Ther; 2021 Apr; 12(1):246. PubMed ID: 33879242 [TBL] [Abstract][Full Text] [Related]
57. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768 [TBL] [Abstract][Full Text] [Related]
58. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329 [TBL] [Abstract][Full Text] [Related]
60. Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective. Veilleux O; Claveau JS; Alaoui H; Roy J; Ahmad I; Delisle JS; Kiss T; Bambace NM; Bernard L; Cohen S; Sauvageau G; Fleury I; Mollica L; Roy DC; Serroukh Y; Lachance S Transplant Cell Ther; 2022 Mar; 28(3):145-151. PubMed ID: 34954149 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]